Hypofractionated and Accelerated Radiotherapy With Subcutaneous Amifostine Cytoprotection as Short Adjuvant Regimen After Breast-Conserving Surgery: Interim Report

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 4, 2009, Pages 1173-1180

  Koukourakis, Michael I ^a   Tsoutsou, Pelagia G ^a   Abatzoglou, Ioannis M ^a   Sismanidou, Kyriaki ^a   Giatromanolaki, Alexandra ^a   Sivridis, Efthimios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Acceleration; Amifostine; Breast cancer; c erbB 2 expression; Hypofractionation; Radiotherapy

Indexed keywords

ACCELERATED RADIOTHERAPY; AMIFOSTINE; BREAST CANCER; BREAST CONSERVING SURGERY; C-ERBB-2 EXPRESSION; CYTOPROTECTION; DISTANT METASTASIS; HYPOFRACTIONATION; IN-FIELD; INTERIM REPORTS; LOCAL CONTROL; LUNG FIBROSIS; OVER-EXPRESSION; RELAPSE RATES; TUMOR BED;

PATIENT MONITORING; SURGERY; TOXICITY;

RADIOTHERAPY;

AMIFOSTINE; DEXAMETHASONE; TROPISETRON;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CELL PROTECTION; DISTANT METASTASIS; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FATIGUE; FEVER; FOLLOW UP; HUMAN; HYPOGLYCEMIA; HYPOTENSION; LUNG FIBROSIS; MAJOR CLINICAL STUDY; NAUSEA; NECROLYTIC SYNDROME; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RASH; TISSUE NECROSIS; VOMITING;

ADULT; AGED; AMIFOSTINE; BREAST DISEASES; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM PROTEINS; RADIATION-PROTECTIVE AGENTS; RADIODERMATITIS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 67649519410     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.09.016     Document Type: Article

References (26)

1. Vallis K.A., and Tannock I.F. Postoperative radiotherapy for breast cancer: Growing evidence for an impact on survival. J Natl Cancer Inst 96 (2004) 88-89
2. NSABPB-39 RTOG 0413: A randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clin Adv Hematol Oncol 4 (2006) 719-721
3. Dickler A. Technology insight: MammoSite-A new device for delivering brachytherapy following breast-conserving therapy. Nat Clin Pract Oncol 4 (2007) 190-196
4. Whelan T., MacKenzie R., Julian J., et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 94 (2002) 1143-1150
5. Bentzen S.M., Agrawal R.K., Aird E.G., et al., START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet Oncol 9 (2008) 331-341
6. Munshi A., and Budrukkar A. Hypofractionated radiation therapy in breast cancer: A revolutionary breakthrough or a long way to go?. J Clin Oncol 25 (2007) 458-459
7. Kaufman E.L., Jacobson J.S., Hershman D.L., et al. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 26 (2008) 392-398
8. Koukourakis M.I., Giatromanolaki A., Kouroussis C., et al. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): A short, safe, and effective postoperative regimen for high-risk breast cancer patients. Int J Radiat Oncol Biol Phys 52 (2002) 144-155
9. Koukourakis M.I., Giatromanolaki A., Galazios G., et al. Molecular analysis of local relapse in high-risk breast cancer patients: Can radiotherapy fractionation and time factors make a difference?. Br J Cancer 88 (2003) 711-717
10. LENT SOMA tables. Radiother Oncol 35 (1995) 17-60
11. Macejewski B., Taylor J.M., and Wither H.R. Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx. Radiother Oncol 7 (1986) 323-326
12. Koukourakis M.I., Abatzoglou I., Sivridis L., et al. Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy. Anticancer Res 26 (2006) 2437-2443
13. Vinh-Hung V., Voordeckers M., Van de Steene J., et al. Omission of radiotherapy after breast-conserving surgery: Survival impact and time trends. Radiother Oncol 67 (2003) 147-158
14. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (2002) 1233-1241
15. Sartor C.I., Peterson B.L., Woolf S., et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and Leukemia Group B 9344. J Clin Oncol 23 (2005) 30-40
16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365 (2005) 1687-1717
17. Rutqvist L.E., and Johansson H. Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among "high risk" pre- and postmenopausal breast cancer patients. Acta Oncol 45 (2006) 517-527
18. Athas W.F., Adams-Cameron M., Hunt W.C., et al. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst 92 (2000) 269-271
19. Grdina D.J., Shigematsu N., Dale P., et al. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis 16 (1995) 767-774
20. Koukourakis M.I., Kyrias G., Kakolyris S., et al. Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18 (2000) 2226-2233
21. Cassatt D.R., Fazenbaker C.A., Kifle G., et al. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine. Semin Oncol 29 Suppl. (2002) S2-S8
22. Pignol J.P., Olivotto I., Rakovitch E., et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 26 (2008) 2085-2092
23. Bartelink H., Horiot J.C., Poortmans P.M., et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 25 (2007) 3259-3265
24. Meric F., Buchholz T.A., Mirza N.Q., et al. Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol 9 (2002) 543-549
25. Kyndi M., Sørensen F.B., Knudsen H., et al., Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer. J Clin Oncol 26 (2008) 1419-1426
26. Toledano A., Azria D., et al. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: Final results of the ARCOSEIN trial. J Clin Oncol 25 (2007) 405-410